{"id":87328,"date":"2024-11-21T15:46:06","date_gmt":"2024-11-21T15:46:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capitalization-hagens-berman\/"},"modified":"2024-11-21T15:46:06","modified_gmt":"2024-11-21T15:46:06","slug":"edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capitalization-hagens-berman","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capitalization-hagens-berman\/","title":{"rendered":"Edwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion Of Market Capitalization \u2013 Hagens Berman"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"left\">SAN FRANCISCO, Nov.  21, 2024  (GLOBE NEWSWIRE) &#8212; Hagens Berman urges Edwards Lifesciences Corporation <strong>(NYSE: EW)<\/strong> investors who suffered substantial losses to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w24VogJbLBQM9CT6r4KX0vyU39w09LmOUPRA94cGqqEjY61rAdbmhmPDHF8udD_iE_viX6zmkdRHnJzivfQhYeESGq2EkdR3CedP_pQkSnfwOPxt5JPN3iOw3WySv48W\" rel=\"nofollow noopener\" target=\"_blank\" title=\"submit your losses now\">submit your losses now<\/a>.<\/p>\n<p><strong>Class Period: <\/strong>Feb. 6, 2024 \u2013 July 24, 2024<br \/><strong>Lead Plaintiff Deadline: <\/strong>Dec. 13, 2024 <br \/><strong>Visit:<\/strong> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Chq3Yvwv_cLXgxaDlNsL6vpMYj1FcSL_N0067K7G2pUPjXPU8XL7QLVmbZC-sQl2jgtFa7HLbLNaws9823YwIHoe7kP36-5Zpgg1ZGMpCXobJ-8izdrsl4-LRXee_NGb29XXY10EwpvPjZGZnOPt-A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.hbsslaw.com\/investor-fraud\/ew\">www.hbsslaw.com\/investor-fraud\/ew<\/a> <br \/><strong>Contact the Firm Now:<\/strong> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2aTA7GcxS7VNkTV67m2fBC0EyN9Dz56v0EBePNy_yrT-SjWzZeWVFWwN-X8g_PuVFTxNG2O0va7B_F7iyBlnJw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"EW@hbsslaw.com\">EW@hbsslaw.com<\/a> <br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<strong>844-916-0895<\/strong><\/p>\n<p><strong>Class Action Lawsuit Against Edwards Lifesciences Corporation (EW):<\/strong><\/p>\n<p>The litigation is focused on the propriety of Edwards Lifesciences\u2019 disclosures about its core product, the Transcatheter Aortic Valve Replacement (\u201cTAVR\u201d) platform.<\/p>\n<p>More specifically, throughout the Class Period, Edwards Lifesciences repeatedly assured investors that its TAVR platform was positioned for \u201cstrong sustainable growth\u201d well into the future, it could \u201caccelerate growth in 2025 and beyond[,]\u201d TAVR could grow healthy double digit, and it could capitalize on the large percentage of undertreated patients with severe aortic stenosis.<\/p>\n<p>The complaint alleges that the company made misleading statements and failed to disclose that: (i) it did not possess reliable information supportive of its TAVR revenue and growth outlook; (ii) <br \/>TAVR growth was at risk of decelerating; and (iii) its \u201cpatient activation activities\u201d did not reach the low-treatment-rate population.<\/p>\n<p>Investors learned the truth on July 24, 2024, when Edwards Lifesciences announced its Q2 2024 financial results. Among other things, the company revealed that its TAVR sales grew just 5% and slashed its TAVR growth guidance to 5 to 7% from 8 to 10%.<\/p>\n<p>The company blamed the TAVR setback on \u201c[t]he continued growth and expansion of structural heart therapies, including newly approved tricuspid therapies and other fast-growing structural heart therapies put pressure on hospital workflows, which impacted TAVR.\u201d<\/p>\n<p>The next day, July 25, 2024, several analysts downgraded Edwards Lifesciences shares and reduced their price targets. One analyst wrote, \u201c[m]anagement talked about physician capacity as the issue versus demand, but we struggle with that explanation [\u2026.] [b]ecause aortic stenosis has a higher mortality [\u2026] management looks to be implying that doctors could be prioritizing lower mortality patients over higher mortality ones \u2013 which we struggle to understand.\u201d<\/p>\n<p>These events drove the price of Edwards Lifesciences shares down $27.25 (-31%) on July 25, 2024, wiping out over $16 billion of shareholder value in a single day.<\/p>\n<p>\u201cWe\u2019re investigating whether Edwards Lifesciences may have misled investors about the true business and growth prospects for TAVR amid an apparently increasing competitive market,\u201d said Reed Kathrein, the Hagens Berman partner leading the investigation.<\/p>\n<p>If you invested in Edwards Lifesciences and have substantial losses, or have knowledge that may assist the firm\u2019s investigation, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w24VogJbLBQM9CT6r4KX0vyU39w09LmOUPRA94cGqqFGwJxWmM84f8dm18YCQyvwdReVtwI7iqZZk1Y7YijFzVtAWrm9QvW0A1iB1nUGp_6RHQ5o5JZxAFss-uhZxNqd\" rel=\"nofollow noopener\" target=\"_blank\" title=\"submit your losses now\">submit your losses now<\/a> \u00bb<\/p>\n<p>If you\u2019d like more information and answers to frequently asked questions about the Edwards Lifesciences case and our investigation, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uZBqAxjg1qmIE0QQi7E8P4aEKVPcOSXELMn_nmWCTHLGlUz1OpGP5CAoueVRF1AcbvntwQnVJs09eHMiJlRUBYvu38fpBHYVNkbeRxqoe5rsrmcHBaoKOGhT8vRMUYgYNGL-9ybxH3maey0u16UezaHq7BDtlsWnq3SvmiRO3_4=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"read more\">read more<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iwVBUW5U_t0YO8C3jYVrQ9OCUfqZ3MXZYJc6lo5BaFaIEvtNQzW73K2JxwcmWMbfA_BRXuYOzqfLcSCJo-hhxfzZhlufSoxTvTpPep0qLApfboZKoWlI7wxx2r_5euYQ8XZDI0_D3O9GZP4OxiQHaDiLmh06nb3n17D4IVINujs=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\u00bb\"> \u00bb<\/a><\/p>\n<p><strong>Whistleblowers: <\/strong>Persons with non-public information regarding Edwards Lifesciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895<\/strong> or email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2aTA7GcxS7VNkTV67m2fBL6h6hCk_nVyzdz4BlssQpUrzOyZEDaZyTkb7q-B-9koaCUBUeapiY8UnkVbLnPD-w==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"EW@hbsslaw.com\">EW@hbsslaw.com<\/a>.<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mWd6kFz9JfZ8iTE6RTTs3slpEcgvZEHA4rCAiX_Vn0y6tElZYj5b8fOkLGH_KN2RbvxvzOr2Ybvwy1jOmFFw1sVqXsF_Uk4-5UyXMA0aH28=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"About Hagens Berman\">About Hagens Berman<\/a><br \/>Hagens Berman is a global plaintiffs\u2019 rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman\u2019s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UgREuz0DdQhekSYktrBfp7G1cqyW06F4rSxlRXFrzdth0ZMMcgRPk5pO4UVJZb9iXftDzE__cJ4jbhoH4ht_YQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"hbsslaw.com\">hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_lq1u8hRbhv4gZvUGnNj203k1Cemrx5tVXCl8O0d9qwNtEPS-tALyQJXMJYfcZCyKE3L5yzxqmiXY95WezQEAPLzO9z3MMAapncZmXlJpIg=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"@ClassActionLaw\">@ClassActionLaw<\/a>.\u00a0<\/p>\n<p><u>Contact: <\/u><br \/>Reed Kathrein, 844-916-0895<\/p>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Nov. 21, 2024 (GLOBE NEWSWIRE) &#8212; Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 \u2013 July 24, 2024Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com\/investor-fraud\/ew Contact the Firm Now: EW@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":87329,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/51670c91-d369-4a8c-8102-d393de9f6d19","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-87328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/87328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=87328"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/87328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/87329"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=87328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=87328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=87328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}